These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 22388631)

  • 41. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
    Bushnell DL; Bodeker KL
    Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
    Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
    Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase 3 Trial of
    Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
    N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
    Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
    Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.
    Chalkia MT; Stefanoyiannis AP; Chatziioannou SN; Round WH; Efstathopoulos EP; Nikiforidis GC
    Australas Phys Eng Sci Med; 2015 Mar; 38(1):7-22. PubMed ID: 25427548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
    Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
    Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of long-acting somatostatin analogues on the uptake of [
    Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
    Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
    Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
    Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
    Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
    Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G
    Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The next generation of peptide receptor radionuclide therapy.
    Brabander T; Nonnekens J; Hofland J
    Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.